Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant FOLFOX After TME for Locally Advanced Rectal Cancer
NCT02167321Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Dec 2014
- Primary completion
- May 2019
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, folinic acid and fluorouracil in rectal cancer (2 arms), sponsored by Yonsei University. Primary endpoint: Disease Free Survival at 3 years. Status: unknown.
02
Drugs
oxaliplatinfolinic acidfluorouracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT02167321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02167321.